Gerson R, Serrano OA, Álvarez I, Villalobos A

Language: Spanish
References: 18
Page: 63-67
PDF size: 73.91 Kb.

ABSTRACT

Background: In Mexico breast cancer represents the second most frequent tumor among the female population. Several factors are considered like risk for developing breast cancer. It has been informed about a possible relationship between breast cancer and thyroid diseases. Objective: To analize the characteristics that show breast cancer patients serie who have thyroid diseases or that were detected on an oncologic consult. Patients and methods: Women with breast cancer in stages I, IIA and IIB with a thyroid disease history or thyroid dysfunction detected during follow-up were included. T3, T4, TSH and free T4 basal and at 12 months were estimated. Age, clinical stage, oncologic treatment, T3, T4, TSH y free T4, time between breast cancer and thyroid disease, hormonal receptor status and follow-up time were registered. Results: Out of 459 patients 23 (4.9%) women had thyroid disease before diagnosis of breast cancer, and 5 (1.6%) who developed thyroid dysfunction during follow-up, and 2 (0.4%) with simultaneous diagnosis. Mean age 50 ± 12.05 years, range 23 to 82. Ten (33.3%) cases of hypothyroidism, 9 (30%) hyperthyroidism, 8 (26.6%) benign thyroid nodules, 2 papillary carcinoma and one of viral thyroiditis, 3.3% were observed. Mean time from thyroid disease to breast cancer 211.3 ± 116.7 months, median 192 and range 36 to 504, while the lapse from breast cancer to thyroid dysfunction 22.8 ± 21.7 months, median 18 and range: 3 to 60. From those last patients four patients received CAF, 80%; 3 radiation therapy, 60% and 3 tamoxifen, 60%. Differences among T3, T4, TSH and free T4 serum levels did not were seen, p › 0.05. Mean follow-up 7.29 months, range 12 to 216, median 28. Three cases of systemic recurrence, 10%. Conclusions: The frequency of thyroid diseases detected before or after breast cancer diagnosis is low. Hypothyroidism, hyperthyroidism and benign thyroid nodules are mean entities observed in breast cancer. Thyroid diseases could anticipate breast cancer up to 16 years, while thyroid dysfunction after mammary malignancy it could see earliest, 2 to 3 years. It is necessary a long study with wide population for evaluating real impact of thyroid diseases over the breast cancer incidence.

REFERENCES

1. Registro histopatológico de neoplasias en México. Dirección General de Epidemiología, Secretaría de Salud, 1998: 1-38.

2. Winer EP, Morrow M, Osborne CK et al. Malignant tumors of the breast. In: DeVita VT, Hellman S, Rosemberg SA. Cancer: Principles and practice of oncology. 6a ed. Philadelphia, USA: Lippincott-Williams and Wilkins, 2001: 1651-1726.

3. Dueñas GA. El gen del receptor de estrógenos en el cáncer de mama. Amigo o enemigo? Rev Inst Nal cancerol 1999; 45: 38-42.

4. Smyth P. The thyroid and breast cancer: A significant association? Ann of Med 1997; 29: 189-191.

5. Giani C, Fierabbracci P, Bonacci R et al. Relationship between breast cancer and thyroid disease: Relevance of autoimmune thyroid disorders in breast malignancy. J Clin Endocrinol Metab 1996; 81: 990-994.

6. Adamopoulos DA, Vassilaros S, Kapolla N et al. Thyroid disease in patients with benign and malignant mastopathy. Cancer 1986; 57: 125-128.

7. Kurland LT, Annegers JF. Breast cancer and Hashimoto thyroiditis. Lancet 1976; april 10: 808.

8. Smyth PPA, Smith DF, McDermott EWM et al. A direct relationship between thyroid enlargement and breast cancer. J Clin Endocrinol Metab 1996; 81: 937-941.

9. Mitra I, Hayward JL. Hypothalamic-pituitary axis in breast cancer. Lancet 1974; 11: 885-888.

10. Hellman S. Principles of cancer management: Radiation therapy. In: De Vita VT, Hellman S, Rosemberg SA. Cancer: principles and practice of oncology. 6a ed. Philadelphia, USA: Lippincott-Williams and Wilkins, 2001: 265-288.

11. Gordon D, Beastall GH, McArdle CS et al. The effect of tamoxifen therapy on thyroid function tests. Cancer 1986; 58: 1422-1425.

12. Kapdi CC, Wolfe JN. Breast cancer: Relationship to thyroid supplements for hypothyroidism. JAMA 1976; 236: 1124-1127.

13. Zidan J, Bubenstein W. Effect of adjuvant tamoxifen on thyroid function in posmenopausal women with breast cancer. Oncology 1999; 43-45.

14. Mamby C, Love RR, Lee KE. Thyroid function test changes with adjuvant tamoxifen therapy in postmenopausal women with breast cancer. J Clin Oncol 1995; 13: 854-7.

15. Athanassiou IK, Ntalles K, Markopoulos C et al. Thyroid function in postmenopausal women with breast cancer on tamoxifen. Eur J Gynaec Oncol 1998; 2: 150-154.

16. Takatani O, Okumoto T, Kosano H et al. Relationship between the levels of serum thyroid hormones or estrogen status and the risk of breast cancer genesis in Japanese women. Cancer Res 1989; 49: 3109-3112.

17. Sellitini DF, Tseng YL, Latham KL. Nuclear thyroid hormone receptors in CH3/HeN mause mammary glands and spontaneous tumors. Cancer Res 1983; 43: 1030-1038.

18. Ross JS, Fletcher JA. The HER-2/neu oncogen in breast cancer: prognostic factor, predictive factor and target for therapy. The Oncologist 1998; 3: 237-252.